Literature DB >> 18071298

Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures.

C Shen1, Q Meng, G Zhang, W Hu.   

Abstract

BACKGROUND AND
PURPOSE: Rifampicin has been extensively reported to exacerbate the hepatotoxicity of isoniazid in patients with tuberculosis. However, this was controversially claimed by previous reports using rat models. This study evaluated the effect of rifampicin on isoniazid-induced hepatocyte toxicity by using human and rat hepatocytes in tissue-like culture. EXPERIMENTAL APPROACH: Hepatocytes in tissue-like gel entrapment were used to examine isoniazid toxicity, as shown by cell viability, intracellular glutathione content and albumin secretion. For demonstration of the differential effects of rifampicin on human and rat hepatocytes, induction by rifampicin of cytochrome P450 (CYP) 2E1, a major enzyme associated with isoniazid hepatotoxicity, was detected by 4-nitrocatechol formation and RT-PCR analysis. KEY
RESULTS: Rifampicin (12 microM) enhanced isoniazid-induced toxicity in human hepatocytes but not in rat hepatocytes. Enhanced CYP 2E1 enzymic activity and mRNA expression were similarly detected in human hepatocytes but not in rat hepatocytes. Both rat and human hepatocytes in gel entrapment were more sensitive to isoniazid treatment compared with the corresponding hepatocytes in a monolayer culture. CONCLUSIONS AND IMPLICATIONS: The difference in induction of CYP 2E1 by rifampicin between rat and human hepatocytes accounted for the difference in exacerbation of isoniazid hepatocyte toxicity by rifampicin, with more significant toxicity in gel entrapment than in monolayer cultures. Thus, human hepatocytes in tissue-like cultures (gel entrapment) could be an effective model for hepatotoxicity research in vitro, closer to the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071298      PMCID: PMC2259215          DOI: 10.1038/sj.bjp.0707611

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2.

Authors:  Stefan Wilkening; Augustinus Bader
Journal:  J Biochem Mol Toxicol       Date:  2003       Impact factor: 3.642

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.

Authors:  Yi-Shin Huang; Herng-Der Chern; Wei-Juin Su; Jaw-Ching Wu; Shi-Chuan Chang; Chi-Huei Chiang; Full-Young Chang; Shou-Dong Lee
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  The differential cytotoxicity of methotrexate in rat hepatocyte monolayer and spheroid cultures.

Authors:  T M Walker; P C Rhodes; C Westmoreland
Journal:  Toxicol In Vitro       Date:  2000-10       Impact factor: 3.500

5.  Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog.

Authors:  C Lu; A P Li
Journal:  Chem Biol Interact       Date:  2001-05-16       Impact factor: 5.192

6.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

Authors:  Ajay Madan; Richard A Graham; Kathleen M Carroll; Daniel R Mudra; L Alayne Burton; Linda A Krueger; April D Downey; Maciej Czerwinski; Jameson Forster; Maria D Ribadeneira; Liang-Shang Gan; Edward L LeCluyse; Karl Zech; Philmore Robertson; Patrick Koch; Lida Antonian; Greg Wagner; Li Yu; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2003-04       Impact factor: 3.922

7.  In vitro studies on the toxicity of isoniazid in different cell lines.

Authors:  Christina E Schwab; Helga Tuschl
Journal:  Hum Exp Toxicol       Date:  2003-11       Impact factor: 2.903

8.  Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

Authors:  Shrutidevi Agrawal; Inderjit Singh; Kanwal Jit Kaur; Shantaram R Bhade; Chaman Lal Kaul; Ramesh Panchagnula
Journal:  Int J Pharm       Date:  2004-05-19       Impact factor: 5.875

Review 9.  Strategies for using in vitro screens in drug metabolism.

Authors:  Nick Plant
Journal:  Drug Discov Today       Date:  2004-04-01       Impact factor: 7.851

10.  Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.

Authors:  Leah M Hesse; Yumiko Sakai; Daesety Vishnuvardhan; Albert P Li; Lisa L von Moltke; David J Greenblatt
Journal:  J Pharm Pharmacol       Date:  2003-09       Impact factor: 3.765

View more
  14 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

2.  Induction of protective autophagy against apoptosis in HepG2 cells by isoniazid independent of the p38 signaling pathway.

Authors:  Tian-Guang Zhang; Yi-Mei Wang; Jun Zhao; Ming-Yu Xia; Shuang-Qing Peng; Takashi Ikejima
Journal:  Toxicol Res (Camb)       Date:  2016-04-04       Impact factor: 3.524

3.  CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.

Authors:  Jie Cheng; Kristopher W Krausz; Feng Li; Xiaochao Ma; Frank J Gonzalez
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-08       Impact factor: 4.219

4.  Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.

Authors:  Anika Mann; Thomas Pelz; Knut Rennert; Alexander Mosig; Michael Decker; Amelie Lupp
Journal:  Hum Cell       Date:  2017-05-19       Impact factor: 4.174

5.  Protective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicity.

Authors:  Tung-Yuan Shih; Ton-Ho Young; Herng-Sheng Lee; Chung-Bao Hsieh; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

6.  Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.

Authors:  Caihong Qu; Xiaoyan Li; Zhenda Zheng; Jieming Zhu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?

Authors:  Jiang Yue; Renxiu Peng
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 8.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

9.  Protective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice.

Authors:  Yong Lian; Jing Zhao; Peiyu Xu; Yimei Wang; Jun Zhao; Li Jia; Ze Fu; Li Jing; Gang Liu; Shuangqing Peng
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

10.  Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation.

Authors:  Charan Singh; Laxmikant Jodave; Tara Datt Bhatt; Manjinder Singh Gill; Sarasija Suresh
Journal:  Toxicol Rep       Date:  2014-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.